<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998035</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM3752</org_study_id>
    <nct_id>NCT01998035</nct_id>
  </id_info>
  <brief_title>Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies</brief_title>
  <official_title>Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Replapsed and Refractory Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Owen A. O'Connor</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, phase I/IIa, 3 x 3 dose escalation study with an initial phase I
      followed by a disease focused phase II.

      The primary objective of the phase I is to determine the maximum tolerated dose (MTD) and
      dose limiting toxicity (DLT) of the combinations of oral 5-azacitidine and romidepsin in
      patients with lymphoma. The safety and toxicity of this combination will be evaluated
      throughout the entire study.

      If the combination of oral 5-azacitidine and romidepsin is found to be feasible and an MTD is
      established, the phase II part of the study will be initiated.

      Phase II will consist of a 2 stage design of the combination of oral 5-azacitidine and
      romidepsin for patients with relapsed or refractory T-cell lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive oral 5-azacitidine and romidepsin, administered as follows: oral
      5-azacitidine from Days 1-14 (Dose cohorts -1 to 5) or Days 1-21 (Dose cohort 6); and
      romidepsin administered intravenously on Days 8 (Dose cohorts 1-4) of a 28 day cycle, and Day
      22 (Dose cohorts 5 and 6) of a 35 day cycle. Cohorts of 3 patients will be enrolled
      sequentially as outlined in the dose escalation scheme. Once the MTD is reached the Phase II
      part of the protocol will be initiated in patients with T-Cell Lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Maximum tolerated dose (MTD) of the combination of oral 5-azacitidine &amp; romidepsin</measure>
    <time_frame>up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Number of dose limiting toxicities (DLTs) of the combination of oral 5-azacitidine &amp; romidepsin</measure>
    <time_frame>up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Number of toxicities experienced by patients with the combination of oral 5-azacitidine and romidepsin</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Overall response rate (ORR) (complete + partial response) of the combination of oral 5-azacitidine and romidepsin in patients with relapsed/refractory T-Cell Lymphoma</measure>
    <time_frame>Up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I: Maximum number of cycles received</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of dose delays at the maximally tolerated dose (MTD)</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Number of dose reductions at the maximally tolerated dose (MTD)</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Overall response rate (ORR) of the study population</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I &amp; II: Progression free survival (PFS) of the study population</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I &amp; II: Duration of response (DOR) of the study population</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Prevalence of overall survival of the patients with T-cell lymphoma on study</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Positive response to clinical outcome indicating potential pre-treatment biomarkers by relating correlative sample data to clinical data on each patient.</measure>
    <time_frame>Up to 1.5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Phase I &amp; II: Prevalence of pharmacodynamic markers of drug effect indicated in optional paired tissue biopsies</measure>
    <time_frame>Up to 1.5 years</time_frame>
    <description>Samples taken from baseline and post treatment timepoints will be compared to try to identify pharmacodynamic markers of drug effect.</description>
  </other_outcome>
  <other_outcome>
    <measure>Phase I: Concentration time curve (AUC) for the combination of oral 5-azacitidine &amp; romidepsin in cycle 1</measure>
    <time_frame>Up to 1.5 hours</time_frame>
    <description>Samples will be drawn at various timepoints and run in aggregate during the course of the study.</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Lymphoid Malignancies</condition>
  <condition>Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>R/O: Level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Day 8), cycle length (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 100 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 200 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (10 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8 and 15), cycle length (28 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 300 mg (Days 1-14) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R/O: Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 5-Azacitidine 300 mg (Days 1-21) Romidepsin (14 mg/m2 rounded to 14 mg/m2, Days 8, 15 and 22), cycle length (35 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romidepsin</intervention_name>
    <description>Romidepsin is an anti-cancer (&quot;antineoplastic&quot; or &quot;cytotoxic&quot;) chemotherapy drug. Romidepsin is classified as a &quot;Histone Deacetylase Inhibitor&quot;.
Dose escalation (10, 14 mg/m2)</description>
    <arm_group_label>R/O: Level -1</arm_group_label>
    <arm_group_label>R/O: Level 1</arm_group_label>
    <arm_group_label>R/O: Level 2</arm_group_label>
    <arm_group_label>R/O: Level 3</arm_group_label>
    <arm_group_label>R/O: Level 4</arm_group_label>
    <arm_group_label>R/O: Level 5</arm_group_label>
    <arm_group_label>R/O: Level 6</arm_group_label>
    <other_name>Istodax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral 5-Azacitidine</intervention_name>
    <description>A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.
Dose escalation (100, 200, 300 mg)</description>
    <arm_group_label>R/O: Level -1</arm_group_label>
    <arm_group_label>R/O: Level 1</arm_group_label>
    <arm_group_label>R/O: Level 2</arm_group_label>
    <arm_group_label>R/O: Level 3</arm_group_label>
    <arm_group_label>R/O: Level 4</arm_group_label>
    <arm_group_label>R/O: Level 5</arm_group_label>
    <arm_group_label>R/O: Level 6</arm_group_label>
    <other_name>5-AC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase I: Histologically confirmed relapsed or refractory non-Hodgkin lymphoma or
             Hodgkin lymphoma (WHO criteria), with no accepted curative options.

          -  Phase II: Relapsed or refractory T-cell lymphoma, including patients with central
             nervous system (CNS) involvement or lymphomatous meningitis are allowed on study.

          -  Relapsed or refractory disease following frontline chemotherapy. No upper limit for
             the number of prior therapies. Patients may have relapsed after prior autologous or
             allogeneic stem cell transplant.

          -  Evaluable Disease in the Phase I, and measurable disease for the Phase II.

          -  Age &gt; or = 18 years.

          -  ECOG performance status &lt; or = 2.

          -  Patients must have adequate organ and marrow function.

          -  Negative urine or serum pregnancy test for females of childbearing potential.

          -  All females of childbearing potential must use an effective barrier method of
             contraception during the treatment period and for at least 1 month thereafter. Male
             subjects should use a barrier method of contraception during the treatment period and
             for at least 3 months thereafter.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Prior Therapy

               -  Exposure to chemotherapy or radiotherapy within 2 weeks prior to entering the
                  study or those who have not recovered from adverse events due to agents
                  administered more than 2 weeks earlier.

               -  Systemic steroids that have not been stabilized ( ≥ 5 days) to the equivalent of
                  ≤10 mg/day prednisone prior to the start of the study drugs.

               -  No other concurrent investigational agents are allowed.

          -  History of allergic reactions to Oral 5-azacitidine or Romidepsin.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women.

          -  Nursing women.

          -  Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of
             the cervix). If there is a history of prior malignancy, the patient must be
             disease-free for ≥ 3 years.

          -  Patients known to be Human Immunodeficiency Virus (HIV)-positive.

          -  Patients with active hepatitis A, hepatitis B, or hepatitis C infection.

          -  Concomitant use of CYP3A4 inhibitors.

          -  Any known cardiac abnormalities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Owen A O'Connor, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Rojas</last_name>
    <phone>212-326-5720</phone>
    <email>cr2393@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Rojas</last_name>
      <phone>212-326-5720</phone>
      <email>cr2393@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Owen A O'Connor, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Owen A. O'Connor</investigator_full_name>
    <investigator_title>Professor of Medicine &amp; Experimental Therapeutics, Director, Center for Lymphoid Malignancies, Co-Director, Program for Lymphoid Development &amp; Malignancies, Herbert Irving Comprehensive Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Lymphoid Malignancies</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non-hodgkin Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Anaplastic Large Cell Lymphoma</keyword>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>Small Lymphocytic Lymphoma</keyword>
  <keyword>Mantle Cell Lymphoma</keyword>
  <keyword>Marginal Zone Lymphoma</keyword>
  <keyword>Burkitt Lymphoma</keyword>
  <keyword>Waldenstrom Macroglobulinemia</keyword>
  <keyword>Peripheral T-cell Lymphoma</keyword>
  <keyword>Cutaneous T-cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Romidepsin</mesh_term>
    <mesh_term>Histone Deacetylase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

